The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) have released new recommendations for the Tetanus, diphtheria, and pertussis (Tdap) vaccine and the Meningococcal Conjugate Vaccine (MCV4). These recommendations become effective immediately in the Texas Vaccines for Children (TVFC) Program and are outlined below.

**Tdap Vaccine**
Changes in Tdap recommendations include vaccinating TVFC-eligible children with Tdap at ages 7 to 10 years, and eliminating the minimum interval from the previous diphtheria-toxoid (Td) vaccination.

Tdap is indicated for a single booster dose at age 11 or 12 years if the childhood DTP/DTaP vaccination series has been completed. Tdap is preferred over Td as adolescents are susceptible to pertussis due to waning immunity, though Td may be indicated rather than Tdap in special situations (more information is available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5503a1.htm?s_cid=rr5503a1_e).

Adolescents who did not receive Tdap at age 11 or 12 should receive a single dose of Tdap in place of a single Td booster dose. Tdap can be administered regardless of interval since the last tetanus or diphtheria containing vaccine.

Tdap should be given to children 7 through 18 years of age who:
- have received tetanus and diphtheria containing vaccines (DT or Td) instead of DTP/DTaP for some or all doses of the childhood series;
- have received fewer than 5 doses of DTP/DTaP or 4 doses if the fourth dose was administered at age 4 years or older; or
have never been vaccinated against tetanus, diphtheria, or pertussis (no doses of pediatric DTP/DTaP/DT or Td). The preferred schedule is a single Tdap dose, followed by a dose of Td four weeks after the first dose and a second dose of Td 6-12 months later. If not administered as the first dose, Tdap can be substituted for any of the other Td doses in the series. For Tdap catch-up, refer to the following chart.

More information about the catch-up is available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5503a1.htm?s_cid=rr5503a1_e.

**MCV4 Vaccine**

Changes in MCV4 recommendations include a booster dose for healthy children 11-18 years, five years after the first dose. There are currently two licensed MCV4 products. Menactra ®, manufactured by Sanofi Pasteur, and Menveo ® manufactured by Novartis Vaccines and Diagnostics, Inc. Both products are licensed for use in persons aged 2 through 55 years of age.
For additional information on any specific vaccines, such as dosages or contraindications and precautions, please refer to the package insert.

If you have questions regarding this policy, please contact your TVFC consultant, Health Service Region, or Local Health Department representative.